Episurf Reports 2Q19 Revenue of SEK 1.1MM (USD $0.1MM), +37.5% vs. 2Q18

• Gross order intake for the quarter increased 21% year over year.
• Orders for the Episealer knee implant increased 14% vs. prior year, with 49 orders.
• U.S. patient recruitment for the EPIC Knee study is ready to commence.
• The company received patent approvals in the U.S., Japan and Europe
• Entered into an agreement with a U.S.-based orthopedic company for use of Episurf’s AI-based imaging tool Epioscopy in allograft surgeries. Details and financial considerations of the agreement are currently confidential.

Segment sales and growth on an as-reported basis is as follows ($MM).

Sources: Episurf

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.